Journal
PHARMACOLOGY
Volume 89, Issue 1-2, Pages 53-57Publisher
KARGER
DOI: 10.1159/000335367
Keywords
Bioavailability; Almorexant; Orexin; Pharmacokinetics
Categories
Funding
- Actelion Pharmaceuticals Ltd.
Ask authors/readers for more resources
Background/Aims:The aim of this single-center, open-label study was to assess the absolute bioavailability of an oral (tablet) versus intravenous formulation of almorexant in healthy subjects. Methods: A pilot phase in 3 healthy male subjects, which preceded the main study, consisted of a single 30-min intravenous infusion of 10 mg al morexant. Its objectives were to ensure the tolerability of the intravenous formulation and to select the intravenous dose for the main study. The main study was a randomized, two-way crossover study in 20 healthy subjects (10 males and 10 females). Subjects received a single oral dose of 200 mg al morexant and a single 30-min intravenous infusion of 20 mg almorexant. Results: All 23 subjects completed the study as planned. Almorexant was well tolerated; the main observed adverse events were somnolence and fatigue. A geometric mean total body clearance of 431/h (95% Cl 39-47) and a volume of distribution of 683 liters (95% Cl 552-845) were determined. The absolute oral bioavailability of almorexant was 11.2% (90% Cl 9.6-13.1). Conclusion: Almorexant seems to possess a pronounced first-pass effect and metabolism. Copyright (C) 2012 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available